Palo Alto Medical Foundation/California Pacific/Sutter Research Institute, Palo Alto, California; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York; Penn State Hershey Medical Center, Hershey, Pennsylvania; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, Arizona; Stanford University School of Medicine, Stanford, California; Duke University, Durham, North Carolina; Indiana University, Indianapolis, Indiana; The Ohio State University Medical Center, Columbus Ohio; Oklahoma University Hospital, Stephenson Cancer Center, Oklahoma City, Oklahoma; Moffitt Cancer Center, Tampa, Florida; Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland; Women's Cancer Center of Nevada, Las Vegas, Nevada; University of California at Irvine, Irvine, California; and Riverside Methodist Hospital, Columbus, Ohio.
Corresponding author: John K. Chan, MD, Division of Gynecologic Oncology, Palo Alto Medical Foundation/California Pacific/Sutter Research Institute, San Francisco, CA; email: [email protected].
This study was supported by National Institutes of Health grants to NRG Oncology (1 U10 CA180822), NRG Operations (U10CA180868), and UG1CA189867 (NCORP).
The authors thank Denise Cobb Hale and The Fisher Family Fund for administrative support.
Financial Disclosure Dr. John K. Chan received funds from NRG/GOG for consortium trial participation and funds for research, consultant, and speaker bureau from AbbVie, Acerta, Aravive, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Merck, Myriad, Roche, Seagen. Bradley J. Monk is on the board for the GOG Foundation and is a paid consultant. Brittany Davidson received money from GSK. Joan L. Walker disclosed that Stephenson Cancer Center is an NRG Oncology Laps site and she is NCORP PI, but unrelated to this study. Robert Wenham received GOG funds for consortium trial participation, money from Regeneron, Tesaro/GSK, and Genentech. In the past 3 years, he has received funds from Seagen, Ovation Diagnostics, AbbVie, Clovis, AstraZeneca, Prescient Therapeutics, and Merck. Yovanni Casablanca received funding from AstraZeneca. Nick M. Spirtos received funding from John Wiley and Sons, and NRG Oncology. The other authors did not report any potential conflicts of interest.
A list of Gynecologic Oncology Group member institutions that participated in the primary treatment studies can be found in Appendix 1, available online at https://links.lww.com/AOG/C539.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews are available at https://links.lww.com/AOG/C540.
